Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.61 |
| ▸ | YARS1 | P54577 | 2/20 | 0.57 |
| ▸ | MME | P08473 | 3/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.50 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | CPA1 | P15085 | 1/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9852111 | 1.00 | SLC7A5 (0.61) | SLC7A5YARS1MMEOPRD1OPRM1 | |
| SCHEMBL30622026 | 1.00 | SLC7A5 (0.61) | SLC7A5YARS1MMEOPRD1OPRM1 | |
| SCHEMBL30839504 | 0.95 | SLC7A5 (0.55) | SLC7A5YARS1OPRD1OPRM1ENPEP | |
| SCHEMBL31031588 | 0.93 | SLC7A5 (0.56) | SLC7A5YARS1MMEOPRD1OPRM1 | |
| SCHEMBL29386283 | 0.92 | OPRD1 (0.58) | SLC7A5YARS1MMEOPRD1OPRM1 | |
| SCHEMBL31643051 | 0.92 | ENPEP (0.55) | SLC7A5YARS1OPRD1OPRM1ENPEP | |
| SCHEMBL30423707 | 0.92 | OPRM1 (0.58) | MMEOPRD1OPRM1OPRK1 | |
| SCHEMBL30494285 | 0.91 | SLC7A5 (0.51) | SLC7A5YARS1OPRD1ENPEP | |
| SCHEMBL1574161 | 0.91 | SLC7A5 (0.65) | SLC7A5YARS1MMEOPRD1OPRM1 | |
| SCHEMBL1574158 | 0.91 | SLC7A5 (0.65) | SLC7A5YARS1MMEOPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4659592-A1 | FLAVOR ENHANCING COMPOSITION, MANUFACTURING METHOD THEREFOR, AND METHOD FOR ENHANCING FLAVOR OF FOOD PRODUCT | House Foods Corporation (JP) | 2025-12-10 | — | — | EP | claimed |
| EP-4659591-A1 | TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT | House Foods Group Inc. (JP) | 2025-12-10 | — | — | EP | claimed |
| US-12377110-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2025-08-05 | — | — | US | claimed |
| WO-2024078588-A9 | NEW USE OF PEPTIDE COMPOUND IN PREPARATION OF COMPOSITION FOR SKIN AGING REPAIR | 深圳市维琪科技股份有限公司 | 2024-09-26 | — | — | WO | claimed |
| WO-2024162421-A1 | FLAVOR ENHANCING COMPOSITION, MANUFACTURING METHOD THEREFOR, AND METHOD FOR ENHANCING FLAVOR OF FOOD PRODUCT | ハウス食品株式会社 | 2024-08-08 | — | — | WO | claimed |
| WO-2024162422-A1 | TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT | ハウス食品グループ本社株式会社 | 2024-08-08 | — | — | WO | claimed |
| WO-2024078588-A1 | NEW USE OF PEPTIDE COMPOUND IN PREPARATION OF COMPOSITION FOR SKIN AGING REPAIR | 深圳市维琪科技股份有限公司 | 2024-04-18 | — | — | WO | claimed |
| US-20230084521-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-03-16 | — | — | US | claimed |
| CN-115581633-A | Novel use of peptide compounds in preparation of composition for skin aging repair | 深圳市维琪医药研发有限公司 | 2023-01-10 | — | — | CN | claimed |
| US-20220105050-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-04-07 | — | — | US | claimed |
| EP-0457314-A1 | Nutrient compositions containing peptides | CLINTEC NUTRITION COMPANY (US) | 1991-11-21 | — | — | EP | claimed |
| US-20260144893-A1 | COMPOSITIONS AND METHODS COMPRISING PROGRAMMABLE SNRNAS FOR RNA EDITING | REGENERON PHARMACEUTICALS, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12529164-B2 | Rationally designed, synthetic antibody libraries and uses therefor | ADIMAB, LLC (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4659591-A1 | TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT | House Foods Group Inc. (JP) | 2025-12-10 | — | — | EP | disclosed |
| EP-2610338-A1 | METHOD FOR PRODUCING SUBSTANCE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-20130130317-A1 | METHOD FOR PRODUCING SUBSTANCE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2013-05-23 | — | — | US | disclosed |
| EP-0127108-B1 | PROCESS FOR PREPARING POLYPEPTIDES | MERCK & CO. INC. (US) | 1986-12-30 | — | — | EP | disclosed |
| US-4510083-A | POTASSIUM, CESIUM OR RUBIDIUM CARBONATE BUFFER FOR COUPLING OF AMINO ACID N-CARBOXYANHYDRIDE WITH ANOTHER AMINO ACID OR PEPTIDE | MERCK & CO., INC. (US) | 1985-04-09 | — | — | US | disclosed |
| EP-0127108-A1 | Process for preparing polypeptides | MERCK & CO. INC. (US) | 1984-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144893-A1 | COMPOSITIONS AND METHODS COMPRISING PROGRAMMABLE SNRNAS FOR RNA EDITING | NSUN3, RBM26, SNRPD2 | SLC7A5 869/4885YARS1 106/4885MME 2384/4885 |
| US-12377110-B2 | Fospropofol methods and compositions | FOS, FOSB, PFAS | SLC7A5 2919/4885YARS1 4808/4885MME 2240/4885 |
| US-12529164-B2 | Rationally designed, synthetic antibody libraries and uses therefor | FCGR3B, HRH3, CYTH3 | SLC7A5 975/4885YARS1 2466/4885MME 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.